Prevention and treatment of synucleinopathic and amyloidogenic disease
First Claim
1. A method of treating, reducing the risk of, lessening the severity of, or delaying the outset of a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising administering to a patient having or at risk of the disease an effective regime of an antibody that specifically binds to human alpha-synuclein (SEQ ID:
- 1), wherein the antibody is 1H7 (ATCC accession number PTA-8220) or a humanized or chimeric form thereof.
8 Assignments
0 Petitions
Accused Products
Abstract
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson'"'"'s disease.
-
Citations
4 Claims
-
1. A method of treating, reducing the risk of, lessening the severity of, or delaying the outset of a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising administering to a patient having or at risk of the disease an effective regime of an antibody that specifically binds to human alpha-synuclein (SEQ ID:
- 1), wherein the antibody is 1H7 (ATCC accession number PTA-8220) or a humanized or chimeric form thereof.
- View Dependent Claims (2, 3, 4)
Specification